TW200829565A - Pyrrole derivatives, preparation thereof and therapeutic use thereof - Google Patents
Pyrrole derivatives, preparation thereof and therapeutic use thereof Download PDFInfo
- Publication number
- TW200829565A TW200829565A TW096143731A TW96143731A TW200829565A TW 200829565 A TW200829565 A TW 200829565A TW 096143731 A TW096143731 A TW 096143731A TW 96143731 A TW96143731 A TW 96143731A TW 200829565 A TW200829565 A TW 200829565A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituted
- unsubstituted
- alkyl
- atom
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 62
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 2
- -1 hydroxy, hydroxymethyl Chemical group 0.000 claims description 61
- 239000000460 chlorine Substances 0.000 claims description 47
- 125000004429 atom Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000007789 gas Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012305 Demyelination Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- ZSBPGGQJRPMLCZ-UHFFFAOYSA-N 1,2,3,4,4a,10-hexahydroacridine Chemical compound C1=CC=C2NC(CCCC3)C3=CC2=C1 ZSBPGGQJRPMLCZ-UHFFFAOYSA-N 0.000 claims 1
- 241000219112 Cucumis Species 0.000 claims 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 101001100204 Homo sapiens Ras-related protein Rab-40A-like Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100038416 Ras-related protein Rab-40A-like Human genes 0.000 claims 1
- 102000005890 Spectrin Human genes 0.000 claims 1
- 108010019965 Spectrin Proteins 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000003935 attention Effects 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003337 fertilizer Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical group CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 238000011282 treatment Methods 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 9
- 239000004305 biphenyl Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 201000007930 alcohol dependence Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229930003827 cannabinoid Natural products 0.000 description 5
- 239000003557 cannabinoid Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- RHJCXFBKZTTWBQ-UHFFFAOYSA-N C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.[La] Chemical compound C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.[La] RHJCXFBKZTTWBQ-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- 239000003324 growth hormone secretagogue Substances 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VONGYFFEWFJHNP-UHFFFAOYSA-N methyl 1h-pyrrole-2-carboxylate Chemical compound COC(=O)C1=CC=CN1 VONGYFFEWFJHNP-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- YBCUDQAIIXWIIR-UHFFFAOYSA-N (2,4-diphenylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 YBCUDQAIIXWIIR-UHFFFAOYSA-N 0.000 description 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- NRESDXFFSNBDGP-UHFFFAOYSA-N (4-bromophenyl)hydrazine Chemical compound NNC1=CC=C(Br)C=C1 NRESDXFFSNBDGP-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- LBAANPWUYHUCJL-UHFFFAOYSA-N 1,2-dimethylhydrazine hydrazine Chemical compound CNNC.NN LBAANPWUYHUCJL-UHFFFAOYSA-N 0.000 description 1
- RABZYUWMIDILPP-UHFFFAOYSA-N 1,3-bis(sulfanyl)propane-1,2,3-triol Chemical compound SC(C(C(O)S)O)O RABZYUWMIDILPP-UHFFFAOYSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 1
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 1
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical compound C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 1
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 1
- CZUGFKJYCPYHHV-UHFFFAOYSA-N 3-methylthiopropanol Chemical compound CSCCCO CZUGFKJYCPYHHV-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940124801 5-HT6 antagonist Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 101100522278 Caenorhabditis elegans ptp-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 1
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- NMWQEPCLNXHPDX-UHFFFAOYSA-N Glybuzole Chemical compound S1C(C(C)(C)C)=NN=C1NS(=O)(=O)C1=CC=CC=C1 NMWQEPCLNXHPDX-UHFFFAOYSA-N 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000583145 Homo sapiens Membrane-associated phosphatidylinositol transfer protein 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229940124139 Hydroxysteroid dehydrogenase inhibitor Drugs 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122942 Leptin receptor agonist Drugs 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 102100030353 Membrane-associated phosphatidylinositol transfer protein 1 Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N Minaline Natural products OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AUQMGYLQQPSCNH-UHFFFAOYSA-L NIR-2 dye Chemical compound [K+].[K+].C1=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C=C2C(C2(C)C)=C1[N+](CC)=C2C=CC=CC=C1C(C)(C)C2=CC(C(O)=O)=CC=C2N1CCCCS([O-])(=O)=O AUQMGYLQQPSCNH-UHFFFAOYSA-L 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241000237509 Patinopecten sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 229910001347 Stellite Inorganic materials 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001441730 Triacanthidae Species 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- DXPOSRCHIDYWHW-UHFFFAOYSA-N Xamoterol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 DXPOSRCHIDYWHW-UHFFFAOYSA-N 0.000 description 1
- MTJLQTFHJIHXIX-GDUXWEAWSA-N [(1s,2s)-2-[2-[3-(1h-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1h-naphthalen-2-yl] 2-methoxyacetate;hydron;dichloride Chemical compound Cl.Cl.C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 MTJLQTFHJIHXIX-GDUXWEAWSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- FKYDFGYBTUVVHL-UHFFFAOYSA-N acetic acid hexylurea Chemical compound C(C)(=O)O.C(CCCCC)NC(=O)N FKYDFGYBTUVVHL-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- FMTFZYKYVZBISL-HUVRVWIJSA-N azacosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 FMTFZYKYVZBISL-HUVRVWIJSA-N 0.000 description 1
- 229950005866 azacosterol Drugs 0.000 description 1
- YWQGBCXVCXMSLJ-UHFFFAOYSA-N beclobrate Chemical compound C1=CC(OC(C)(CC)C(=O)OCC)=CC=C1CC1=CC=C(Cl)C=C1 YWQGBCXVCXMSLJ-UHFFFAOYSA-N 0.000 description 1
- 229950009252 beclobrate Drugs 0.000 description 1
- 229960004374 befunolol Drugs 0.000 description 1
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- KTFZDGGBFILTSA-UHFFFAOYSA-N beta-Sitosterin Natural products CCC(CC)CCC(C)C1CCC2C1CCC3C2CC=C4CC(O)CCC34C KTFZDGGBFILTSA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960003588 bevantolol Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RSMSFENOAKAUJU-UHFFFAOYSA-L bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RSMSFENOAKAUJU-UHFFFAOYSA-L 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 229960001035 bopindolol Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229950002568 bucumolol Drugs 0.000 description 1
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 1
- 229950009385 bufetolol Drugs 0.000 description 1
- AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 1
- 229950008581 bunitrolol Drugs 0.000 description 1
- VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 1
- ZZRMYOZQUCUWFT-UHFFFAOYSA-N but-3-yn-2-amine Chemical compound CC(N)C#C ZZRMYOZQUCUWFT-UHFFFAOYSA-N 0.000 description 1
- DBKDSOCVEYXXSO-UHFFFAOYSA-N butane;pyrrolidine Chemical compound CCCC.C1CCNC1 DBKDSOCVEYXXSO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- AJEHNBIPLQJTNU-UHFFFAOYSA-N cyanomethyl acetate Chemical compound CC(=O)OCC#N AJEHNBIPLQJTNU-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BSGUKFWHMSPLDO-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(phenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.P(c1ccccc1)[c-]1cccc1 BSGUKFWHMSPLDO-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- IKBJGZQVVVXCEQ-UHFFFAOYSA-N efonidipine hydrochloride Chemical compound Cl.CCO.CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 IKBJGZQVVVXCEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960002711 epanolol Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- QUDXDEBDLQNOAF-UHFFFAOYSA-N ethyl hexanoate hexanoic acid Chemical compound CCCCCC(O)=O.CCCCCC(=O)OCC QUDXDEBDLQNOAF-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010433 feldspar Substances 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000868 fluvastatin sodium Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229960003236 glisoxepide Drugs 0.000 description 1
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229950005232 glybuzole Drugs 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 229960004440 glymidine Drugs 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- LLLQJQUWSSBNHX-UHFFFAOYSA-N hydrazine 4-methylmorpholine Chemical compound CN1CCOCC1.NN LLLQJQUWSSBNHX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- DALYXJVFSIYXMA-UHFFFAOYSA-N hydrogen sulfide dimer Chemical compound S.S DALYXJVFSIYXMA-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- QTZFSVVIXMRRLW-UHFFFAOYSA-N indanorex Chemical compound C1=CC=C2CC(C(N)CC)(O)CC2=C1 QTZFSVVIXMRRLW-UHFFFAOYSA-N 0.000 description 1
- 229950004952 indanorex Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960001468 mefenorex Drugs 0.000 description 1
- XXVROGAVTTXONC-UHFFFAOYSA-N mefenorex Chemical compound ClCCCNC(C)CC1=CC=CC=C1 XXVROGAVTTXONC-UHFFFAOYSA-N 0.000 description 1
- 229960001961 meglutol Drugs 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- 229960005125 metahexamide Drugs 0.000 description 1
- XXYTXQGCRQLRHA-UHFFFAOYSA-N metahexamide Chemical compound C1=C(N)C(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 XXYTXQGCRQLRHA-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical group COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- ZYWUVGFIXPNBDL-UHFFFAOYSA-N n,n-diisopropylaminoethanol Chemical compound CC(C)N(C(C)C)CCO ZYWUVGFIXPNBDL-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- XPPXHQUWVYMTDM-UHFFFAOYSA-N nicoclonate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)OC(=O)C1=CC=CN=C1 XPPXHQUWVYMTDM-UHFFFAOYSA-N 0.000 description 1
- 229950011138 nicoclonate Drugs 0.000 description 1
- UAORFCGRZIGNCI-UHFFFAOYSA-N nifenalol Chemical compound CC(C)NCC(O)C1=CC=C([N+]([O-])=O)C=C1 UAORFCGRZIGNCI-UHFFFAOYSA-N 0.000 description 1
- 229950000096 nifenalol Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001199 olmesartan medoxomil Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQZJKHIIQFPZCS-UHFFFAOYSA-N propylurea Chemical compound CCCNC(N)=O ZQZJKHIIQFPZCS-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- VIHDTGHDWPVSMM-UHFFFAOYSA-N ruthenium;triphenylphosphane Chemical compound [Ru].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 VIHDTGHDWPVSMM-UHFFFAOYSA-N 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000003751 serotonin 6 antagonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960005383 terodiline Drugs 0.000 description 1
- UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003352 tertatolol Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 description 1
- 229960000822 tiadenol Drugs 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 229960004928 xamoterol Drugs 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- 150000008494 α-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
Description
200829565 九、發明說明: 【發明所屬之技術領域】 本發明係關於4,5-二苯基吡咯_2·曱醯胺衍生物,關於其 製備及其醫療應用。 【先前技術】 具有大麻素CB〗受體親和性之4,5_二苯基处洛-2-甲酿胺 衍生物已在專利申請案WO 2006/024 777中描述。 目箣已經發現在啦洛氮上具有特定取代基之新型*,5 _二 ‘苯基吡咯-2-甲醯胺衍生物,其具有中樞及/或外周大麻素 CB!受體拮抗劑特性。 【發明内容】 本發明係關於對應於下式之化合物:
C-NRR
其中: -A代表: (CVC6)伸烷基, 或多次; 其未經取代或經(CrCd烷基取代 基團-(0¾
(ch2)p- 其中m=0、1或2且p=l或1 125790.doc 200829565 -Ri代表氫或(CVC4)烧基; -R2代表: 基,“經取代或經以下基團取代:三 氣甲基n (Cl.c4m氧基、a原子⑽邮基 •非芳族(VCu碳環基團,農夫 ,、禾經取代或經以下基團 取代一或多次:(cvcj炫其、、* _ 4)坑基經基、氰基或(CVC4)
Ο 燒氧基、基團CORu或氟原子; •二氫茚基; • 1,2,3,4 -四氫-1-或 _2_ 蔡基; .5至7個原子之單氧或單硫雜環基團,其未經取代或 經(C1-C4)烧基取代一或多次; .5至7個原子之單氮雜環基團,其未經取代或細 (Cl_C收基取代—或多次,而且氮原子經心4)烧 基本基¥基、(Ci-C4)燒氧幾基或((Vc4)烧酿基 取代,苯基或苄基未經取代或妳広
取代或經鹵素原子或(C1_C 烧基、二氟甲基、經基戎ΓΓ l^(Cl_C4)烷氧基取代一或多 , 本并嗟吩基或,B朵基歹 ^ 4等基團未經取代或經 (Ci-C4)烧基取代一或多次; 具有非芳族C3_ClG碳環基團之(Ci_c3)伸院基,盆未 ;取代或經(以)燒基、經基、心綱基或氛 基或基團CORu取代一或多次· 具有含5至7個原子之單氣、罝 平虱早硫或早氮雜芳族或非 125790.doc 200829565 雜芳族雜環基團之(Cl_c3)伸烷基,其未經取代或經 (C1-C4)燒基取代一或多次; •具有吲哚基或苯并噻吩基之(Ci_C3)伸烷基,該吲哚 基或苯并噻吩基未經取代或經(Ci-C4)烷基取代一或 夕-人且该伸燒基未經取代或經羥基、甲基或甲氧基 或經基團COR12取代; •具有(CVC4)烷硫基之(C1-C3)伸烷基;
Cj •其中伸烷基為(C!_C3)之苯基伸烷基,其在伸烷基上 未經取代或經甲基、羥基、羥基甲基、甲氧基或甲 氧基甲基或基團CORi2取代一或多次,且其在苯美 上未經取代或在苯基上經一或多個選自_素原子及 (CrC4)烷基、三氟甲基、(Ci_C4)烷氧基或三氟甲氧 基之相同或不同取代基取代; •二苯甲基或二苯甲基甲基; •基團 NR10Rn ; 或RiAR2連同其所連接之氮原子一起構成: •嗎啉基 土 丹禾經取代 苯基、节基、苯并間二氧雜環戊缚基、苯并間 Μ塔 rV:、咕盆兩甘丄、一 k . 經 ^ H巫 '本开間二 氧雜環戊稀基甲基或四氫吱喃其 陶暴蜮基取代或經 COR12或CH2COR12S團取代,节其 土本身未經取代或 經一或多個鹵素原子取代或經一武 ^ ^ 或多個甲氧基或曱 氧基甲基取代; 或六氫吡啶-1-基、吡咯啶_丨_基 X I 雜 % 丁烷-1- 125790.doc 200829565 基,其未經取代或經獨立選自下列之取代基取代一 或兩次: -說原子或基團(Ci-C4)烷基、羥基、氰基、 cor12、nr13r14、nhcor15、CH2COR12、 S02Alk ;或 s〇2nr13r14 ; -苯基、节基或u比啶基,該苯基、节基或吼啶基 基團未經取代或經各自獨立選自!I素原子及甲 基、三氟甲基、羥基、(Ci_c4)烷氧基或氰基之 取代基取代一或多次; -六氫吼啶-1-基、吡咯啶-i _基或氮雜環丁烷-i _ 基,該六氫吡啶-1-基、吡咯啶-1-基或氮雜環丁 烧-1-基基團未經取代或經氟原子或(Cl_C4)烷 基、(Ci-C4)烧氧基、經基、三氟曱基或〇cf3基 團取代一或多次; R3 R4、R5、R6、R7及R8各自獨立代表氯或鹵素原 子、基團 CN、S(0)nALK 或 0S(0)nALK、基團(CVC7) 烷基(其未經取代或經各自獨立選自氟原子及基團 OALK、S(0)nALK、0S(0)nALK及 NHS02Alk之取代 基取代一或多次)、或基團(C^Cd烷氧基(其未經取代 或經一或多個各自獨立選自氟原子及基團OALK、 S(0)nALK、0S(0)nALK 及 NHS02Alk之取代基取代); -R9代表基團-OH、-CN、-C02H、NR13R14、-CONR13R14 、-NRiCORn、-CONHNH2、-CONHOH、-C0NHS02Alk 、-S(0)nAlk、-SO2CF3、_S〇2NRi3Ri4、-NRiSC^Alk、 125790.doc -10 - 200829565 -NRiSC^CFs、-NR^SC^NRuRm ;或選自下列之基團:
?H
OH HO c -R10表示氫原子或甲基; -Rn代表((VC6)烷基、苯基或(C3_Cig)環烷基,該苯基 及%烷基基團未經取代或經一或多個獨立選自齒素原 子及(Ci-C4)烷基或三氟甲基之取代基取代; _ 4R1G及Rn連同其所連接之氮原子一起構成飽和或不 飽和、橋接或非橋接之可能包含螺環烷碳且可能包含 選自Ο及N之第二雜原子的4至11個原子之雜環基團, 〇 該基團未經取代或經各自獨立選自羥基、(CrCd烷基 或(c^C4)烷氧幾基或C0Ri2基團、或苯基(其未經取代 _ 或經一或多個獨立選自卣素原子及(C^C:4)烷基之取代 基取代)之取代基取代一或多次; _ R二代表(Cl-C4)烧基、苯基、节基、(cvc4)^氧基或 二氟甲基或基團nr13r14 ; -ur14各自獨立代表氫原子或視情況經—或多個基 團OH、F或OALK取代之ΓP甘 上 %代之(CVC6)烷基,或Ri3或Ri4連 125790.doc • 11 · 200829565 同其所連接之氮原子-起構成可能包含選自氮、氧或 硫原子之4_至7-員雜環基團; -R15代表(C!_C4)烷基或三氟甲基; • η代表0、1或2 ; 或多個氟原 ALK代表(CKC4)烧基,其未經取代或經一 子取代; -Aik代表烷基; 以及其鹽、溶劑合物及水合物。 Γ
式⑴化合物可包含—或多個不對稱碳原子。因此其可以 對映異構體或非對映異構體之形式存在。該等對映異構體 及非對映異構體以及其混合物(包括外消旋混合物)構成本 發明之一部分。 式⑴化合物可以㉟《g复加成鹽之形式存在。言亥等鹽較佳 由醫藥上可接受之酸來製備,但用於(例如)純化或:離: (I)化合物之其它酸之鹽亦構成本發明之一部分。 本發明之化合物亦可以水合物或溶劑合物形式,即以與 y個或多個水分子或與—溶劑締合或結合之形式存在。^ 等水合物及溶劑合物亦構成本發明之一部分。 術語,,炫基"意指直鏈或支鏈基團,例如(具體而言):甲 基、乙基、丙基、異丙基、丁基、異丁基、第三_丁基、 正-戊基、異戊基、正己基、異己基,該甲基對於(C1_C4) 烷基而言較佳且第三_丁基、2_甲基_2-丁基及3,3-二甲 基-2-丁基對於(C4-C1())烧基而言較佳。 術語”伸烷基”意指直鏈二價基團。 125790.doc -12- 200829565 術語"烧氧基"意指直鏈或支鏈基團,甲氧基較佳 氣或溴 術語,,齒素原子"意指氟、氯、填或峨原子;氟、 原子較佳。 非务族C3 - C丨2碳環基團句括林拉 I图包括橋接或稠合單環或多環基 團。該等單環基團包括環烧基,例如環丙基、環丁A、产 戍基、環己基、環庚基及環辛基;環己基與環戊基㈣Γ 該稍合、橋接或螺環烷二環或二 — 飞一衣基團包括(例如)降莰烷
基、坎基、異莰基、降金剛烷基、金剛烷基、螺[5 5]十一 炫基、二環[2.2」]庚院基、二環[321]辛院基及二環 [3.1.1]庚烷基。 術語”可能包含諸如0stN等第二雜原子之4至"個碳原 子之飽和或不飽和雜環基團"意指諸如嗎琳_4_基、六氯吼 啶-1-基、六氫吡嗪小基…比咯咬+基或八氫環戊[小比 咯-2-基,六氫吡啶基及嗎啉_4•基較佳。 術語”5至7個原子之單氮雜環基團”意指諸如六氣吼咬冬 基或吡咯啶-3-基等基團,六氫吡啶基較佳。 術語”5至7個原子之單氧雜環基團”意指諸如四氫呋喃 基、四氫-2开·吼喃基或氧雜環庚烷基等基團;四氫呋喃基 較佳。 術語”5至7個原子之單硫雜環基團”意指諸如四氫噻吩基 或四氫硫吼喃基等基團。 術語”5至7個原子之雜芳族雜環基團”意指諸如吡啶基、 口比咯基、噻吩基或呋喃基等基團。 詞語π可能包含選自氮、氧、或硫原子之第二雜原子的 125790.doc -13· 200829565 5·至7-員含氮雜環基團,,尤 A ^ ^ ,、係心虱雜環丁烷基、吡咯啶 土 氣σ比嗓基、六氫^比 -,^ ^ 疋基、亂呼基、嗎啉基、硫嗎啉 丞或六虱吡嗪基。 根據本發明,下列尤為突出:
- jSl.中 A ^ 代表未級取代或經(CrC3)伸烷基取代一或多 次之(Cl_C6)伸烷基之式IA化合物; 其中-A-代表伸笨基之式18化合物;
-其中i代表下列基團之式1C化合物:
其中-A-代表下列基團之式m化合物: 'CHrH0^CH2- ^ 其中-A*代表下列基團之式IE化合物: •其中-A-代表下列基團之式IF化合物: ^η2.〇η2-^〇^ΟΗ2.. 取代基心至以9係如對式⑴化合物所定義。 根據本發明,較佳之式(I)化合物為以下彼等化合物,其 中: ’、 125790.doc -14- 200829565 • R丨代表氫且I代表基®NR】〇Rn,其令心〇及連同 f所連接之氮原子一起構成個碳原子的飽和雜 %基團,其未經取代或經(C〗-C4)烷基取代一或多 次, -或心及尺2連同其所連接之氮原子一起構成六氫0比 定-1-基,其經苯基、苄基、吡咯啶基、六氫吡 啶-1-基或4,4-二氟六氫吡啶基取代及經氰基、 (G-C3)烷醯基、胺基羰基、甲烷磺醯基、n_甲基磺 醯基或N,N-二甲基磺醯基取代; -或心與R2 一起代表六氫吨嗪-1-基,其經苯并間二氧 雜環戊烯基或苯并間二氧雜環戊烯基甲基或經苄基‘ 取代,該苯并間二氧雜環戊烯苯并間二氧雜環戊烯 苄基本身未經取代或經一或多個_素原子取代或經 一或多個甲氧基或甲氧基甲基取代; 且/或R3、R4、R5、R6、1及以各自獨立代表氫或鹵 素原子或甲氧基; -A-R9具有針對(I)所述之值之一; 以及其鹽、溶劑合物及水合物。 尤其突出之式I化合物為以下彼等化合物,其中·· -Ri代表氫且R2代表六氫吼啶-1-基或(Ci_C3)伸烷基基 團,其經苯基取代且經甲氧基或曱氧羰基取代; -或1^代表氫且R2代表其中伸烷基為(Ci_c3)伸烧基之 苯基伸烷基’其在伸烷基上未經取代或在伸燒基上 經甲基、羥基、羥基曱基、曱氧基或曱氧基曱2取 125790.doc •15- 200829565 代’且在本基上未經取代或在苯基上經鹵素原子或 甲基、三氟甲基、羥基或甲氧基取代一或多次; -或1及化連同其所連接之氮原子一起代表六氫处 咬-1-基,其經苯基或六氫吼啶-1-基且經醯基、胺基 羰基或氰基4-偕-雙取代; -或Ri及R2 一起代表六氫σ比唤-1 -基,其經苯并間二氧 雜環戊烯基甲基或苄基4-取代,該苄基自身未經取 代或經鹵素原子取代; R6為4-氯或甲氧基且R3及R4代表2,4-二氯或2-氯; R5、R7及R8代表氫原子; -Α代表基團(CH2)q,其中q=2、3、4或5 ; -R9代表選自:-C02H、-NHS〇2CF3、-NHS02CH3、 -S02CH3之基團; 以及其鹽、溶劑合物及水合物。 具體而έ,杈佳之式(I)化合物係以下彼等化合物,其 中: • NRih代表:
125790.doc -16 - 200829565 -R3、R4及R6各自代表素原子; •尺5、R7及汉8各自代表氫原子; -A代表未經取代或經甲基取代一或多次之节基或 (c2-c5)伸烷基; "R9 代表基團 CN、C〇2H、S〇2CH3、NHS02CH3 或 nhso2cf3 ; 以及其鹽、其溶劑合物及其水合物。 突出之式(I)化合物係以下彼等化合物,其中:
-NRiR2代表選自下列之基團··
-以3、R4及R6各自代表_素原子; -R5、R7及R8各自代表氫原子; _ A-R9代表選自-(CH2)5_c〇2、_(CH2)3_NHS〇2CF3、 -(CH2)3NHS02CH3、-(CH2)3-S02Me之基團; 以及其鹽、其溶劑合物及其水合物。 在本發明之化合物中,尤其可提及者係下列化合物: 6 [5-(4 -胺基甲醯基·[j,4’]二六氫吡淀-卜基羰基)_2_(4_ 125790.doc -17- 200829565 氯苯基)-3_(2,4-二氣苯基)比洛基]己酸; -1-({5_(4-溴苯基χ(2,4-二氯苯基)-1-[2-(曱基磺醯基) 乙基]-1//-咣咯-2_基}羰基)-4-苯基六氫吡啶-4-甲醯胺; -1-(1,3-苯并間二氧環戊烯-5-基-甲基)-4-({5-(4-溴苯 基)-4-(2,4-二氯-苯基)-1-[2-(甲基磺醯基)乙基]_1好比咯-2-基}幾基)六氫°比嗓; -N-(l-苄基-2-甲氧基乙基)-5-(4-溴苯基)-4-(2,4-二氯苯 基)-1-[2-(甲基磺醯基)乙基]-1//-吼咯-2-甲醯胺; -1’-{[5-(4-氯苯基)-4-(2,4-二氯苯基)-1-{3-[(曱基磺醯 基)胺基]-丙基比咯基]羰基}-1,4’-二六氫吡啶-4,· 甲醯胺; -1’·{[5-(4-氯苯基)_4-(2,4-二氯苯基)-1-{3-[(三氟甲基磺 醯基)-胺基]-丙基吡咯-2-基]羰基}-1,4’-二六氫吡 啶-4’-甲醯胺; -1*-[5-(4-氣苯基)-4-(2,4-二氯苯基)·1-(3-甲院石黃酿基胺 基-丙基)-1Η-吡咯-2-羰基]-4,4-二氟[1,4’]二六氫吡啶基_4,_ 甲醯胺; -Γ-[5-(4-氯苯基)-4-(2,4-二氯苯基)-1-(3 -甲烧石黃酿基胺 基-丙基)-1Η-吡咯-2-羰基M,4-二甲基[1,4,]二六氫吡咬 基-4’-甲醯胺; -5-(4 -氯苯基)-4-(2,4-二氯苯基)-1-(3 -甲烧石黃醯基胺基_ 丙基)-lH-%b^-((S)-l-經基甲基-3 -甲基丁基)-2 -甲醯胺; -l’-[5-(4 -氯苯基)-4_(2,4-二氯苯基)-1_(3_甲烧石黃醯基丙 基)-111-°比洛-2-獄基]-4,4-二甲基-[1,4’]二六氫叱咬基_4,_甲 125790.doc -18- 200829565 醯胺; -其他於表1中列出之化合物; 以及其鹽、其溶劑合物及其水合物。 本發明之標的物亦係製備本發明化合物之方法。 該方法之特徵在於: /、中Ri及R2係如對⑴之定義的式HNR1R2 (m)胺處 理式(II)之酸或該下式之酸的功能衍生物:
一 COOH
⑻ 八中R3 R4、R5、r6、;^7及r8係如對⑴之定義且γ代表 氫原子或基團A_R9、或基團A_R92前體; -若適宜,將取代基γ轉化為基團A_r9。 視情況,將如此獲得之化合物轉化為其鹽或溶劑合物。 術語”基團A-R9之前體”意指可使用彼等熟習此項技術者 所習知之方法隨後轉化為基團A_r9之基團。 了使用之酸(II)之功能衍生物包括醯基氯、肝、混人 酐,其中烷基為直鏈或支鏈之(C1-C4)烷基酯、苄基酯、活 化醋(例如對-硝基苯基酯)、或適宜之活化游離酸,例如經 N,N-二環己基-羰-二醯亞胺或經六氟磷酸苯并三唑_丨_基氧 代叁(二甲基胺基)鱗(B0P)、六氟磷酸鱗苯并三唑基氧 125790.doc -19- 200829565 代-叁(吼咯啶基)(PyBOP)或六氟磷酸N-[l-N-(二曱基胺 基)-1,2,3-三峻并[4,5-13]0比咬-1-基-亞曱基]-1<[-甲基甲烧銨 N_氧化物(HBTU)活化。 因此,在本發明之方法中,藉由亞硫醯氯與式(η)之酸 反應而獲得之1,3吐-3-甲酸醯氯可在諸如氯化溶劑(例如 二氯甲烷、二氣乙烷或氯仿)、醚(例如四氫呋喃或二氧雜 環己烷)或醯胺(例如Ν,Ν-二曱基曱醯胺)等惰性溶劑中於惰 性氣氛下在o°c與室溫之間之溫度下及諸如三乙基胺、Ν_ 甲基嗎啉或吡啶等三級胺存在下與胺HNRiR2反應。 一種變化形式在於藉由使氣甲酸乙酯與式(π)酸在諸如 二乙胺等鹼存在下反應來製備式(II)酸之混合酸酐及使其 與胺HNRiR2在諸如二氣甲烷等溶劑中於惰性氣氛下在室 溫下及諸如三乙基胺等鹼存在下反應。 根據一變化形式,其中取代基RsSR8之一代表羥基苯基 之化合物可藉由使其中取代基代表甲氧基苯基之式⑴化合 物在諸如二氯曱烷等溶劑中及__2〇°C與室溫之間之溫度下 與BBr3反應來製備。 根據另一變化形式,其中取代基r3至r8之一代表
AlkS(0)n0-苯基之式⑴化合物可藉由使其中取代基代表羥 基苯基之式(I)化合物在諸如三乙胺等鹼之存在下在諸如二 氯甲烷等溶劑中及-20°C與室溫之間之溫度下與其中Hal代 表*素原子(較佳氣)之式Hal-S(0)nAlki化物反應來製 備。
Ik後可自反應介質中分離如此獲得之式⑴化合物,且按 125790.doc -20- 200829565 照標準方法純化,例如藉由結晶或層析法。 式(II)化合物及其前體可根據下列反應圖製備: 反應圖1
CO,H 1) SOCl2/AlkOH (a) ] 2) TsCl/NEt3 (ΙΠ) HC=C~CH2-CHNH~Ts (IV) C〇2AIk II S- II o
Aik 二(Q -C4)烧基; Ts = 石黃=1 -Me (IV) +
Cul/Pd(0)肆/Et3N R<5 R 7 (V) (b) -c = C.-CH2-CH-NH-Ts
Rs C02Alk (VI) (VI) IAC03—(c)
F
-21 - 125790.doc 200829565 (IX) + DBU (e)
C〇2Alk - 經由步驟幻、b)及c)製備式(VII)二氫吼咯衍生物係按曰召 J· Chem· Soc· Perkin Trans. 1,2002, 622-628來進行。 用經取代之苯基取代二氫吡咯核係在步驟d)中經由經取 ( 代之式(VIII)苯基硼酸在鈀觸媒,例如肆(三苯美 膦)Pd(〇)、雙一卡基亞基丙酮Is (〇)[Pd(dba)2]、卷(二节芙 亞基丙酮)二鈀(〇)、乙酸鈀Pd(II)[Pd(OCOCH3)2]、二氣(二 苯基膦基二茂鐵)Pd(II) [PdChdppf]存在及鹼存在下之作用 來進行的。 在步驟e)中’經由諸如DBU (1,8•氮雜雙環[54〇]十一 烯)等二胺的作用將氮上之甲苯磺醯基保護基團移除,且 同時將吡咯核芳香化。 〇 根據一一般方法,隨後用式h-A-i之碘化物處理式(χ)化 合物以獲得下式化合物:
(XI)=式(II)酸之酯
然後將式(XI)酯在鹼性介質存在下水解且用胺HNRiR 125790.doc 200829565 (III)處理如此形成之酸(II)以形成本發明之化合物。 根據基團-A-R9之不同值,可使用多種熟習此項技術者 所習知之方法來製備本發明之式(π)化合物及式⑴化合 物。
因此’當製備其中-A-R9代表基團(CH2)3NHS〇2Alk之式 (I)化合物時,該方法可按下列反應圖2來進行: 反應圖2
lk 1) ΚΟΗ 或 LiOH 2) 水性HC1 >
ο 125790.doc -23- 200829565
在偶合劑(例如,HBTU、BOP、PyBOP)及驗(例如, N(Et)3)存在下自化合物(XIII)及R13C02H製備其中A-R9代 表基團-(CH2)2NHCOR13之式⑴化合物。 當製備其中A-R9代表基團-(CH2)2S02Alk之式(I)化合物 時,該方法可按下列反應圖3來進行: 反應囷3
當製備其中A-R9代表基團-(CH2)kS02Alk(其中k=l、2、 3、4、5或6)之式(I)化合物時,該方法可按下列反應圖4來 進行: 125790.doc -24- 200829565
反應圖4
該方法按反應圖2以式(XVI)或式(XVI’)化合物開始藉由 皂化,隨後偶合式NIR2化合物以獲得其中A-R9 = (CH2)2-Alk或 A-R9=(CH2)k-Alk之式(I)化合物。 當製備其中R9代表-COOH基團之式(I)化合物時,該方法 可按下列反應圖5來進行: 反應圖5
125790.doc -25- 200829565
(XVIII)
AlkOOC-A-I或丙烯酸酯 K2C03 或 Triton B
R
(xix)
17KOH 或 LiOH (XIX) 27^i±HCi ^
式HNRiRz (III)胺為習知或經由習知方法(例如彼等在J. Med. Chem·,7, 1964, 619-622 中所述者)製備。
本發明之標的物亦係下式化合物:
其中: 125790.doc -26- 200829565 -χ代表鹵素原子或羥基、(G-C4)烷氧基或苄氧基; -A代表: • (G-C:6)伸烷基,其未經取代或經(C「C3)烷基取代 一或多次; •基團-(CH2)m—^ 其中 m=0、1 或 2且 p=l 或 1 ;
-R3、R4、R5、化6、R7及R8各自獨立代表氫或_素原 子、(CVC6)烷氧基、基團 S(0)nALK、0S(0)nALK 或 (C^C?)烷基,其未經取代或經氟原子或基團0ALK、 S(0)nALK 或 0S(0)nALK 取代一或多次; -R9代表基團-OH、_CN、_C02H、NR13R14、_c〇NR13R14 、-CONHNH2、-CONHOH、_C0NHS02Alk、_S(0)nAlk 、-S02CF3、-S02NR13R14、-NHS〇2Alk、-NHS02CF3、 -NHS〇2NR13R14 ;或選自下列之基團:
-n代表0、1或2 ; -ALK代表(Cl-C4)烷基,其未經取代或經一或多個氟原 子取代; 125790.doc 27- 200829565 -Aik代表(CVC4)烷基; 更具體而言,本發明之標的物係下式化合物:
r6 其中: -X代表鹵素原子或羥基、(C^Cd烷氧基或苄氧基; -R6代表氣或漠原子; -A代表基團(CH2)2、(CH2)3、(CH2)4 或(CH2)5 ; -R9 代表基團-CN、-C02H、-S02CH3、-NHS02CH3 或-nhso2cf3 〇 【實施方式】 以下實例闡述本發明某些化合物之製備。該等實例並非 限制而僅用於闡述本發明。作為實例給出之化合物的數值 係指彼等下表中所給出者,其顯示本發明一些化合物之化 學結構及物理性質。 在該等實例中,使用下列縮寫:
EtOAc :乙酸乙酉旨 DCM :二氯甲烷 DIPEA :二異丙基乙基胺 DMF : N,N-二甲基甲醯胺 125790.doc -28- 200829565 m.p.:熔點 HBTU ·六氟碟酸N-[1_N-(二曱基胺基)_ι,2,3 -三α坐并 [4,5-1)]吡啶-1-基亞曱基]->^曱基甲烷銨>^氧化物 HOBt: 1_經基苯并三口坐 MeOH :甲醇
PyBOP ·六氟鱗酸苯并三唑·丨-基氧基畚(吼咯啶基)鱗 RT :室溫 TBTU ··四氟硼酸2_(1H•苯并三唑-^基兴^弘四甲基 脲鑌 THF :四氫吱喃 在DMSO-d6中於2〇〇 MHz下記錄核磁共振譜。為解釋該 譜,使用下列縮寫: s:單峰;d:雙重峰;t:三重峰;rn :未溶解複合體; mt:多重峰;bs:寬單峰;dd:寬雙重峰。 藉由LC/UV/MS偶合(液相層析法/UV檢測/質譜法)分析 本發明化合物。量測分子峰(MH+)及以分鐘(min)計的保留 時間(Rt)。 條件A : 在30 C下’以〇.4笔升/分鐘之流速使用Symmetry C 1 8 2.1x50毫米、3·5微米管柱。 洗脫液由以下組成: -溶劑A :存於水中之0.005%三氟乙酸(TFA),pH 3.15 ; -溶劑B : 〇·〇〇5% TFA溶於乙腈中之溶液。 梯度: 125790.doc -29- 200829565
官柱溫度:30°C,流速〇·4毫升/分鐘。 在λ=210奈米下實施U V檢測且以正E s Σ化學離子化模 實施質量檢測。
經由二極管陣列檢測器於21〇與彻奈米之間實施㈣檢 測且以正E SI模式實施質量檢測。 製備方法 製備方法1 Α) 2-(((4-甲基苯基)磺醯基)胺基)戊_3_炔酸曱酯 在0 C下將2.5克2-胺基-3-丁炔酸懸浮於45毫升甲醇中。 在此溫度下逐滴添加1.8毫升亞硫醯氣且隨後將該混合物 回流3小時。濃縮該溶液並在低壓下乾燥殘餘物。將所得 材料溶解於60毫升乙腈,隨後添加5.4毫升三乙基胺,然 後添加4.6克甲苯磺醯氯。在室溫下攪拌該混合物19小時 且卩逍後在5 0 C下再擾拌1小時。濃縮後,將粗材料溶解於 二氯甲烧中並用飽和KHSO4水溶液及隨後使用k2C03連續 洗務有機相。將有機相用硫酸鎮乾燥且隨後過慮,最後濃 縮以獲得5 · 1 8克期望化合物。 lH NMR : δ (ppm): 2.35: s: 3H ; 2.45: m: 2H ; 3.45: s: 3H,3.9: dd: 1H ; 7.35: d: 2H ; 7.65: d: 2H ; 8.4: d: 1H。 125790.doc -30· 200829565 B) 5-(4-氯苯基)-2-(4-甲苯績醯基續醯基-胺基)戊-4_快 酸甲酯 將1克來自上述步驟之化合物及0_57克4-氯碘苯溶解於2〇 毫升無水DMF中。在真空下將該溶液脫氣3〇分鐘。然後添 加0.64¾升二乙基胺,隨後添加〇·28克肆(三苯基膦)把(〇) 及〇.1克碘化銅。在室溫下於氬蒙氣下攪拌該混合物19小 時。將粗反應材料濃縮並使用環己烷/乙醯乙酸(8〇/2〇 ; V/V)在矽膠上層析純化。回收到1克化合物。 lH NMR : δ (ppm): 2.35: s: 3H ; 2.70-2.80: m: 2H ; 3.45: s: 3H ; 4.05: dd: 1H ; 7.35: m: 4H ; 7.4: d: 2H ; 7.65: d: 2H ; 8.51: d: 1H。 C) 5-(4-氣苯基)·4·蛾-1-(4-甲苯磺醯基磺醯基)-2,3_二 氮-1丑-吡咯-2-甲酸甲酯 在〇°C下及1克碳酸鉀存在下將丨克上述步驟中所獲得之 化合物溶解於5毫升無水乙腈中。在此溫度攪拌下,分成 若干小份添加2克固體碘。使該混合物在24小時内回復至 室溫。使用硫代硫酸鈉溶液中止反應直到脫色時為止,並 用二氣甲烷萃取有機相。將其用硫酸鎂乾燥、過濾並濃 縮,獲得1·27克期望化合物。 LC/MS(條件 A)M=517,Rt=l〇.8 分鐘。 D) 5-(4-氯苯基)-4-(2,4-二氣苯基)4•甲苯磺醯基磺醯 基_ 2,3 - 一·氮-1丑-咐*鳴* - 2 _甲酸甲醋 在48毫升碳酸鈉溶液(2 N)存在下,將15克上述步驟中所 獲得之化合物及6.8克2,4-二氣苯基硼酸溶解於15〇 毛•力' 甲 125790.doc -31 - 200829565 醇及710笔升曱苯之混合物中。將反應介質於氬氣下放置 3〇刀鐘亚Ik後添加七7克肆(三苯基膦)把⑼。在惰性氣氛 下H合液於60 C加熱4小時。冷卻’然後將粗產物漢縮 並藉由在甲苯中於石夕膠上層析來純化。獲得9 7克呈白色 粉末形式之預期化合物。 H NMR . δ (ppm): 2.4: s: 3H ; 2.75-2.95: m: 1H ; 3.8: s: 3H,5.15: d: 1H ; 6.7: d: 1H ; 7.1-7.7: m: 6H。
ί; E) 5-(4-氣苯基)_4-(2,4_二氣苯基咯冬甲酸甲酯 將9.7克在上述步驟中所獲得之化合物溶解於6〇毫升無 水N,N-一甲基甲醯胺中。然後添加5·4毫升dbu(i,8_二氮 雜-雙環[5.4.0]十一烯)並在1〇〇它下將該混合物加熱24小 時。辰縮粗產4勿’添加乙醇,隨後出現白色沈澱。濾去沈 殿,並收集到6克預期化合物。 NMR : δ (ppm); 3.8: s: 3H ; 6.9: s: 1H ; 7.2: s: 1H ; 7·25: s: 2H ; 7.3-7.4: m: 3H ; 7.65: dd: 1H ; 12.4: S: 1H。 F) (4·氣苯基)小(2-|1基乙基M_(2,‘二氣苯基卜w 吼咯-2-甲酸甲酯 在0.5毫升(0.53克)Triton B存在下,將2·5克在上述步驟 中所獲得之化合物溶解於24毫升二氧雜環己烷中。在室溫 下擾拌該混合物!小時,㈣添加2毫升丙烯腈並將該混合 物回流3天。將粗產物濃縮以乾燥並隨後在㈣上層析。 獲得1·4克預期化合物。 LC/MS ·· M=432 ; Rt=12.02分鐘。 G) 1-(3-胺基丙基)_5♦氣苯基)_4_(2,4_二氣苯基)_心 125790.doc -32- 200829565 吡咯-2-甲酸甲酯 將1克在上述步驟中所獲得之化合物溶解於20毫升甲醇 中,添加1.06克CoC12(H20)6並在室溫下攪拌該混合物5分 鐘。接著,逐份添加0.43克NaBH4並在室溫下攪拌該混合 物1小時。用4毫升HC1 (〇·5 N)使該介質酸化。將該化合物 用MgSCU乾燥、過濾並濃縮,然後用EtOAc將其萃取以獲 得1克呈白色泡沫形式之預期化合物。 LC/MS : M=437 ; Rt=8.13分鐘。 € H) 5_(4-氣苯基)-4-(2,4-二氣苯基)-1-(3-曱烷磺醯基胺 基-丙基吡咯-2-甲酸甲酯 在0.61¾升(0.45克)二乙基胺存在下,將1克在上述步驟 中所獲得之胺溶解於20毫升DCM中,隨後在室溫下添加 〇 · 1 7毫升甲基石頁酿乳’並擾掉該混合物4 8小時。將粗反庳 產物乾燥且隨後藉由在矽膠上層析來純化。獲得〇·54克對 應於預期產物之白色泡沫。 ( LC/MS ·· M=515 ; Rt=11.60分鐘。 1)5-(4-氣苯基)-4-(2,4-二氯苯基)-1-(3•甲烷磺醯基胺基· 丙基)-1丑-吡咯·2·甲酸 在5.4宅升氫氧化裡水合物存在下,將㈣克在上述步驟 . 中所獲得之酯在10毫升THF/水混合物(9/1 ; v/v)中皂化。 將該溶液回流19小時並隨後乾燥。用Ηα水溶液(1〇%)將粗 產物酸化並用DCM萃取該產物。將有機相用MgS〇4乾燥, 並隨後過濾並濃縮。獲得0.62克呈白多、、由、士 a 凡王曰色泡沫形式之預期產 物0 125790.doc -33 - 200829565 LC/MS : M=501 ; Rt=10.27分鐘。 製備方法2 5-(4-氣苯基)·4·(2,4-二氣苯基)-1-(2-甲烷磺醯基乙 基)-1及·。比洛-2-甲酸乙酯 藉由如製備方法1,步驟A至E中所述實施操作來製備 5-(4-氣苯基)-4-(2,4-二氯苯基)-1//-。比洛_2-甲酸乙醋。 將0.8克該酯溶解於20毫升DMF中且隨後在室溫下添加 0.32克NaH。攪拌該混合物30分鐘並隨後添加〇·88克甲基 乙烯基砜。將該溶液回流19小時。乾燥介質並藉由在矽膠 上層析來純化殘餘物。收集到〇·2克對應於預期化合物之 膠狀物。 LC/MS : M=499 ; Rt=11.87分鐘。 製備方法3 A) 5_(4_氣苯基)_4-(2,4-二氣苯基)咯 _2-甲酸 將7.8克在製備方法1,步驟E中所獲得之酯溶解於1〇〇毫 升THF/水混合物(90/10 ; v/v)中,隨後添加4·3克氫氧化鋰 水合物並將該混合物回流19小時。乾燥該混合物並隨後用 HC1水溶液(10%)將固體殘餘物洗滌若干次。將所回收之固 體用烘箱乾燥以獲得8.3克預期化合物(白色固體)。 LC/MS : M=365 ; Rt=l〇.57分鐘。 B) 1 …氣苯基)-4-(2,4·二氣苯基比咯-2_羰 基][1,4Ί二六氫吡啶基_4,_曱醯胺 在1·38克(1.89¾升)三乙基胺存在下,將2克如上所獲得 之酸溶解於4G毫升二氯甲烧中,且隨後添加1.27克[1,4Ί二 125790.doc -34- 200829565 六氫吡啶基-4,-甲醯胺,然後添加34*pyB〇p。在室溫下 授拌該混合物24小時。藉由過濾收集到2·3克對應於預期 化合物之白色沈澱。 LC/MS : M=559 ; Rt=7.99分鐘。 製備方法4 A) 氣苯基)_4-(2,4·二氣苯基)-1-(3_甲烷磺醯基丙 基)-1开-α比哈-2 -甲酸乙醋 藉由如製備方法1,步驟Α至Ε中所述實施操作來製備 、 5-(4-氯苯基)-4-(2,4-二氯苯基甲酸乙酯。 將2克該酯溶解於30毫升無水THF中,且隨後添加2.2克 3 -甲基硫基丙-1-醇,然後添加3.9克三苯基膦。在〇。〇下, 添加3.6克DEAD並在室溫下攪拌該混合物19小時。乾燥該 介質並藉由在石夕膠上層析來純化殘餘物。收集到2 · 4克對 應於期望化合物之油狀物。 LC/MS : MH+=482 ; Rt=13.54分鐘。 B) 5-(4-氯苯基)-4·(2,4-二氣苯基)_i-(3-甲烷磺醯基丙 ϋ 基)-1丑-吡咯-2-甲酸乙酯 將2.4克在上述步驟中所獲得之酯溶解於70毫升二氯甲 烷中。在0°C下,逐份添加6克mCPBA並在室溫下攪拌該混 合物2小時。用NaOH水溶液(10%)將介質驗化並用DCM萃 取產物。用MgS04將有機相乾燥,並隨後過濾並濃縮。藉 由在矽膠上層析來純化殘餘物。收集到對應於期望產物之 1.6克微黃色泡沫。 C) 5-(4-氯苯基)-4-(2,4-二氣苯基)-1-(3-曱烷磺醯基- 125790.doc -35- 200829565 丙基)-1及-吡咯-2_甲酸 將1.6克在上述步驟B)中所獲得之酯溶解於24毫升MeOH 中。在室溫下逐份添加1·7克KOH直至氫氧化鉀顆粒完全 溶解,隨後添加4毫升Η2〇。將該混合物回流3小時。一旦 冷卻,即用1 0% HC1水溶液將介質酸化並用DCM萃取產 物。將有機相用MgSCU乾燥,並隨後過濾並濃縮。獲得I」 克對應於期望產物之淺黃色泡沫。 LC/MS : MH+=486 ; Rt=10.27分鐘。 製備方法5 A) 1’-苄基-4,4-二氟[1,4’】二六氫咐》咬基-4’-曱醯胺 根據J· Med. Chem.,7,1964,619-622中所述之方法自 懸浮於15毫升》辰硫酸之1-节基六氮11比17定- 4-i同及市售4,4 -二 氟六氫吼啶合成1.2克1,-苄基-4,4-二氟[1,4,]二六氫吼啶 基-4’-甲腈。 將介質保持在60°C達3小時。將粗產物冷卻至〇°C並隨後 用NHUOH水溶液將其鹼化。用氯仿萃取水相並將有機相用 MgSCU乾燥、過濾且隨後濃縮。藉由在矽膠上層析將其純 化,可獲得0.8克白色固體。 LC/MS : MH+= 338 ; Rt=6.59分鐘。 B) 4,4_二氟[L4,]二六氫吡啶基-4,-甲醯胺 將3.3克上述製備方法5,步驟A)中所獲得之苄基化合物 溶解於30毫升二氣甲烷中並冷卻至〇。〇,然後添加157克 (1.19毫升)氯甲酸氣乙基酯。然後使溫度回復至室溫並攪 拌該混合物3小時。在真空下蒸發掉溶劑,然後將所獲得 125790.doc -36- 200829565 之殘餘物溶解於T醇中並將該混合物回流1小時且隨後再 祭發以乾燥。獲得3.3克對應於預期產物之固體。 實例1 ··化合物1 Α) 6 [5-(4 -胺基甲醯基二六氫吼啶基·羰基) (4-氯苯基)-3-(2,4-二氯苯基),比咯_丨_基]己酸乙酯 將〇·9克製備方法3,步驟B中所獲得之化合物溶解於8毫 升丙酮及3¾升DMF之混合物中。添加〇 66克碳酸鉀,隨 後添加0·32毫升6-溴己酸乙酯。使該混合物回流19小時。 過濾粗產物並將濾液濃縮。獲得對應於預期產物之17克 白色固體,且其不經進一步純化而用於皂化步驟中。 LC/MS : M=702 ; Rt=8.90分鐘。 B) 6 [5-(4 -胺基甲醯基[ι,4’]二六氫α比咬基q,-幾基)_2_ (4-氯苯基)-3-(2,4-二氯苯基p比咯_丨_基]己酸 在0.66克存於1〇毫升THF/水混合物(9/1 ; v/v)中之氫氧 化鋰水合物的存在下將hl克上述酯皂化。回流24小時 後,將該混合物乾燥且隨後用HC1溶液(1〇%)酸化。用 EtOAc萃取產物。用MgS〇4乾燥之後,過濾並隨後濃縮有 機相,獲得粗產物,將該粗產物在矽膠上層析。獲得〇 9 克呈白色固體形式之預期產物。 LC/MS : M=674 ; Rt=8.13 分鐘。 實例2 :化合物11 l’-[5-(4-氯苯基)-4-(2,4-二氯苯基)^(3-曱烷磺醯基丙 基)-1Η-吡咯-2-羰基]-4,4-二甲基[L4,]二六氫吡啶基-4,_甲 醯胺 125790.doc -37- 200829565 在〇·39克(0·54毫升)DIPAE存在下,將〇·5克製備方法4之 步驟C)中所獲得之酸溶解於15毫升DMF中,並添加〇·37克 4,4·二甲基[1,4」二六氫π比啶基_4’-甲醯胺,隨後添加〇.58克 HBTU及0.07克HOBt。在室溫下攪拌該混合物24小時。一 旦經濃縮,即將粗產物在石夕膠上層析。獲得〇 · 3 9克對應於 預期產物之自異丙基醚結晶的固體。 LC/MS : MH+=707 ; Rt=8分鐘。 實例3 :化合物1 〇 氣苯基)-4-(2,4-二氣苯基甲烷磺醯基丙 基)-1Η-吡咯-2-羰基]-4,4-二氟[1,4’]二六氫吡啶基一,_甲 醯胺 在〇·31克(0.42毫升)DIPEA存在下將0·4克在製備方法4之 步驟c)中所獲得之酸溶解於15毫升DMF中,並添加〇·29克 4,4-一氟[1,4’]二六氫吡啶基_4,_甲醯胺,隨後添加〇.58克 HBTU及0.05克H0Bt。在室溫下攪拌該混合物19小時。一 旦經濃縮,即將粗產物在矽膠上層析。獲得〇·3克對應於 預期產物之固體。 LC/MS : ΜΗ+= 730 ; Rt=i〇.36分鐘。 下表闡述本發明若干化合物之化學結構及物理性質。 在該表中,Me意指曱基。 125790.doc •38- 200829565 表1 ο
化合物 (鹽) a_r9 R6 Rs -NR!R2 特徵 m.p. °C LC/MS 1 -(ch2)5-co2h Cl Cl -o<N〇 0 MH+=675 Rt=8.13 102°C 2 -(ch2)2-co2h Cl Cl -〇<◦ 0 MH+=631 Rt=7.54 137〇C 3 cf3co2h -(CH2)2-CN Cl Cl -〇N^> 〇 125〇C 4 -(CH2)2-S02Me Cl Cl —〇〇 Nf C-NH2 0 MH+=665 Rt=7.65 5 -(CH2)2-S02Me Br Cl -o? 0 MH+=702 Rt=10.80 6 -(CH2)2-S02Me Br Cl —N N-CH- v_y 2 135〇C 7 -(CH2)2_S02Me Br Cl ΟΜβΓΛ -NH MH+=665 Rt=11.76 125790.doc -39- 200829565 化合物 (鹽) a_r9 R6 Rs -NR!R2 特徵 m.p. °C LC/MS 8 -(CH2)3-NHS02Me Cl Cl W fj-NH2 0 110°C 9 (HC1) -(ch2)3-nhso2cf3 Cl Cl -o<N〇 w c-nh2 0 231〇C 10 -(CH2)rNHS02Me Cl Cl -n^vnO<p 0 MH+=730 Rt=10.36 11 -(CH2)rS02Me Cl Cl -〇〇:; 0 MH+=707 Rt=8 12 -(CH2)3-NHS02Me Cl Cl -{3<〇C 0 MH+=722 Rt=8.06 13 -(CH2)3-S02Me Cl Cl h2^° P /CH—CH2 -NH MH+=632 Rt=10.33 14 -(CH2)2-S02Me SMe Cl /-y CH3 —〇(0<cH3 0 MH+=705 Rt=7.93 15 -(CH2)rNHS02Me Cl Cl —^^N-CH2 MH+=702 Rt=8.07 16 -(CH2)rNHS02Me OMe Cl -〇<〇: 0 MH+=726 Rt=9.88 17 -(CH2)rNHS02Me OMe H -〇(0< 0 MH+-692 Rt=9.2 125790.doc -40- 200829565 化合物 (鹽) a-r9 R6 Rs -NR1R2 特徵 m.p. °C LC/MS 18 -(CH2)rNHS02Me Cl H -〇〇< 0 MH+=696 Rt=15.16 19 -(CH2)3-S02Me Cl Cl JV OH MH+=585 Rt=10.77 20 -(CH2)3-NHS02Me OMe Cl 〇rP /CH—CH2 -NH MH+=696 Rt=ll 21 -(CH2)3-NHS02Me OMe Cl -o^F N~f yC-NH2 o7 MH+=701 Rt=10.08 22 -(CH2)3-NHS02Me Cl Cl -o^cl N一^1 yC-NH2 〇// MH+=721 Rt=10.96 23 -(CH2)rNHS02Me Cl Cl OMe 、 ch2 V /CH—CH2 -NH MH+=648 Rt=11.47 24 -(CH2)rNHS02Me Cl Cl -o^F w〇//c-nh2 MH+=705 Rt=10.61 25 -(CH2)rNHS02Me F Cl —〇0< 0 MH+=714 Rt=9.89 26 -(CH2)rNHS02Me F Cl — N~/ OH MH+=645 Rt=8.55 27 -(CH2)rNHS02Me F Cl -o^F N~f ,0-NH, 〇/ MH+=689 Rt=10.08 28 -(CH2)3-NHS02Me Cl Cl JV OH MH+=600 Rt=10.82 125790.doc •41 _ 200829565 在 M. Rinaldi-Carmona 等人(FEBS Letters,1994,350, 240-244)所述實驗條件下,式(I)化合物顯示對CBi大麻素 受體優良活體外親和性(IC5〇S5xl〇7M)。 如 M. Bouaboula等人,J. Biol· Chem·,1995, 270,13973-13980 ; M. Rinaldi-Carmona 等人,J. Pharmacol. Exp· Ther·,1996,278,871-878 及 M. Bouaboula 等人,J. Biol. Chem.,1997,272,22330-22339 中所述,式(I)化合物之拮 抗性質係藉助腺苷酸環化酶抑制模型中所獲得的結果加以 證實。 本發明之化合物與存在於腦中之CB!受體的相互作用係 在小鼠中於靜脈内注射或口服投與後籍助[3H]-CP55940離 體結合測試加以檢測,如M· Rinaldi_Carmona等人,FEBS Letters,1994,350,240-244 及 Μ· Rinaldi-Carmona 等人, Life Sciences, 1995, 56, 1941-1947 ! M. Rinaldi-Carmona 等人,J. Pharmacol. Exp. Ther·,2004,310,905-914 及 Rinaldi-Carmona M.等人,JPET 2004,310,905-914 中所 述。 存在於外周之本發明化合物與CB〗受體的相互作用係籍 助在口服投與後CP55940對胃腸運輸之抑制作用恢復的測 試加以檢測,如 M· Rinaldi-Carmona等人,J. Pharmacol. Exp. Ther·,2004,310,905-914 中戶斤述。 式(I)化合物之毒性允許其可用作藥物。 因此,根據其另一態樣,本發明之一標的物係用於人類 或獸醫之藥物,其包括式(I)之化合物或其與一醫藥上可接 125790.doc -42· 200829565 受酸之加成鹽或者式⑴之化合物之溶劑合物或水合物。 因此,在人或動物(尤其哺乳動物,包括(以非限制性方 式)狗、貓、馬、牛及羊)中本發明之化合物可用於治療或 預防與CBi大麻素受體相關之疾病。 舉例而言(且以非限制方式)式(I)之化合物可用作精神藥 物,尤其用於治療精神疾病,包括焦慮、抑鬱、心境障 礙、失眠症、譫妄症、強迫症、—般精神病、精神分裂 症、多動兒童之注意力缺陷及多動障礙(AHD)以及用於治 療與使用精神藥物相關之病纟’尤其在藥物濫用及/或藥 物依賴(包括酒精依賴及煙鹼依賴)之情況下。 本發明式⑴之化合物可用作治療偏頭痛、緊張、源於心 理之疾病、恐慌發作、癲癇症、運動障礙(尤其運動障礙 或帕金森氏症(ParkinSGnis disease)、震顫及肌張力障礙)之 藥物。 本發明式⑴之化合物亦可作為藥物用於治療記憶障礙、 ⑽知P早礙’尤其用於治療老年性癡呆與阿茲海默氏病 (Alzheimer’s disease)以及用於治療注意力或警覺障礙。 此外,式(I)之化合物可作為神經保護劑用於治療局部缺 血、頭顱損傷及治療急性或慢性神經退化性疾病··包括舞 蹈症、亨庭頓氏舞蹈症(Huntingt〇n,s ch〇rea)&T〇urrette症 候群(Toinrette,s syndrome)。 本發明之式(I)化合物可作為藥物用於治療疼痛··神經性 疼痛、急性外周神經性疼痛、源於炎症之慢性疼痛、由抗 癌治療引起之疼痛。 125790.doc -43- 200829565 本發明之式(i)化合物可在人或獸醫中作為藥物用於預防 及治療食欲障礙、嗜好障礙(對糖、碳水化合物、藥物、 酒精或任何促進食欲的物質)及/或進食行為障礙,尤其用 於治療肥胖症或貪食症,以及用於治療„型糖屎病或非胰 島素依賴性糖尿病且用於治療血脂異常及代謝症候群。因 此,本發明之式⑴化合物可用於治療肥胖症及與肥胖症有 關之風險,尤其心血管風險。 而且’本發明之式(I)化合物可作為藥物用於治療或預防 胃腸失調症、腹瀉、潰瘍、嘔吐、膀胱與尿道病症、肝病 (例如慢性肝硬化、纖維化、肝臟脂肪變性及脂肝炎);以 及源自内分泌之病症、心血管病症、低血壓及動脈粥樣硬 化、出血性休克、敗血性休克、哮喘、慢性支氣管炎、慢 座阻塞性肺病、雷講症候群(Raynaud syndrome)、青光 眼、生育障礙、早產、中止懷孕、炎症現象、免疫系統疾 病(尤其自身免疫及神經炎性疾病,例如類風濕性關節 炎、反應性關節炎)、可導致脫髓鞘作用之疾病、多發性 硬化、感染性及病毒性疾病(例如腦炎、中風);及作為醫 藥產品用於抗癌性化學治療、用於治療格-巴二氏症候群 (Guillain-Barr0 syndrome)及用於治療骨病及骨質疏鬆症。 此外,本發明之式(I)化合物可用於預防藥物引起之心臟毒 性。 根據本發明,式(I)化合物尤其可用於製備用於下列之藥 物:用於預防及治療神經疾病,尤其精神分裂症、注意力 及警覺障礙、多動兒童之注意力缺陷及多動障礙(AHD); 125790.doc -44- 200829565 用於預防及治療記憶缺陷及認知障礙;藥物依賴及戒斷, 尤其酒精依賴、尼古丁依賴、酒精戒斷及煙草戒斷;急性 或慢性腎經退行性疾病。 更具體而言,本發明之式⑴化合物可用於製備用於下列 之藥物:用於治療及預防食欲障礙、嗜好障礙、代謝病 症、肥胖症、π型糖尿病、代謝症候群、血脂異常、腸胃 失凋症乂症現象、免疫系統疾病、精神障礙、酒精依賴 及煙鹼依賴。 根據其一態樣,本發明係關於式⑴之化合物、其醫藥上 可接受之鹽及其溶劑合物或水合物用於治療上述病症或疾 病之用途。 根據本發明另一態樣,本發明係關於包含本發明化合物 作為活性成份之醫藥組合物。該等醫藥組合物包含有效劑 篁的至少一種本發明化合物或該化合物之醫藥上可接受之 鹽、溶劑合物或水合物,以及包含至少—種醫藥上可接受 之賦形劑。 該等賦形劑根據醫藥形式及期望之投與方式選自彼等熟 習該項技術者習知之常用賦形劑。 本發明之醫藥組合物可包含式⑴化合物以及一(或多種) 了用於ίσ療上述病症或疾病之其他活性成份。 因此’本發明之標的物亦係包含本發明之式⑴化合物以 及-(或多種)選自下列治療劑類別之一的活性成份的醫藥 組合物: -大麻素CB!受體之另一拮抗劑或變構調節劑; 125790.doc -45· 200829565 -大麻素CB2受體調節劑; -血管緊張素II AT!受體拮抗劑; -轉化酶抑制劑; -鈣拮抗劑; -利尿劑; -β-阻斷劑; _抗高血脂劑或抗高膽固醇血症劑; -抗糖尿病劑; _另一抗肥胖劑或作用於代謝病症之藥劑; _尼古丁促效劑或部分尼古丁促效劑; -抗抑鬱劑、抗精神病劑或抗焦慮劑; -抗癌劑或抗增殖劑; -類鴉片拮抗劑; 以及: -改良記憶之藥劑; -用於治療酒精中毒或戒斷症狀之藥劑; -用於治療骨質疏鬆症之藥劑; -非類固醇或類固醇抗炎劑; -抗感染劑; -鎮痛劑; -平喘劑。 化 普 卸 術語”血管緊張素„ ΑΤι受體拮抗劑,,意指諸如以下之 合物·坎地沙坦(candesartan)、席勒西提(cilexitil)、依 羅炒坦(eprosartan)、厄貝沙坦(irbesartan)、洛沙坦 125790.doc -46- 200829565 (losartan potassium)、奥美沙坦酯(olmesartan medoxomil)、替米沙坦(telmisartan)或纈沙坦(valsartan), 每一該等化合物自身皆可能與一利尿劑(例如,氫氯噻嗓 (hydrochlorothiazide))組合。 術語”轉化酶抑制劑”意指諸如以下之化合物··阿拉普利 (alacepril)、貝那普利(benazepril)、卡托普利(captopril)、 西拉普利(cilazapril)、依那普利(enalapril)、依那普利拉 (enalaprilat)、福辛普利(fosinopril)、咪達普利 (imidapril)、賴諾普利(lisinopril)、莫昔普利(m〇exipril)、 培c朵普利(perindopril)、喹那普利(quinapril)、雷米普利 (ramipril)、螺普利(spirapril)、替莫普利(tem〇capril)、群 多普利(trandolapril)或佐芬普利(zofenopril),每一該等化 合物自身皆可能與一利尿劑(例如氫氯噻嗪或吲達帕胺 (indapamide))或與一鈣拮抗劑(例如,胺氯地平 (amlodipine)、地爾硫卓(diltiazem)、非洛地平(fel〇dipine) 或異搏定(verapamil))組合。 術語π妈拮抗劑π意指諸如以下之化合物:胺氣地平、阿 雷地平(aranidipine)、貝尼地平(benidipine)、苄普地爾 (bepridil)、西尼地平(Cilnidipine)、地爾硫卓、鹽酸依福 地平乙醇(efonidipine hydrochloride ethanol)、法舒地爾 (fasudil)、非洛地平、伊拉地平(isra(jipine)、拉西地平 (lacidipine)、鹽酸樂卡地平(iercanidipine hydrochloride)、 馬尼地平(manidipine)、鹽酸米貝拉地爾(mibefradil hydrochloride) ' 尼卡地平(nicardipine)、硝苯地平 125790.doc -47- 200829565 (nifedipine)、尼伐地平(nilvadipine)、尼莫地平 (nimodipine)、尼索地平(nis〇ldipine)、尼群地平 (nitrendipine)、特羅地林(terodiline)或異搏定。 術語”β-阻斷劑"意指諸如以下之化合物:醋丁洛爾 (acebutolol)、阿普洛爾(alprenolol)、胺磺洛爾 (amosulalol)、阿羅洛爾(ar〇tinolol)、阿替洛爾(atenolol)、 苯呋洛爾(befunolol)、倍他洛爾(betaxolol)、貝凡洛爾 (bevantolol)、比索洛爾(bisoprolol)、波吲洛爾 (bopindolol)、布庫洛爾(bucumolol)、布非洛爾 (bufetolol)、布尼洛爾(bunitrolol) 、 丁 非洛爾 (butofllolol)、卡拉洛爾(caraz〇i〇i)、卡替洛爾(carte〇1〇1)、 卡維地洛(carvedilol)、氯拉洛爾(ci〇ran〇l〇i)、依泮洛爾 (epanolol)、艾司洛爾(esm〇i〇i)、茚諾洛爾(inden〇i〇i)、拉 貝洛爾(labetalol)、蘭地洛爾(iandiolol)、左布諾洛爾 (levobunolol)、左莫普洛爾(ievomopr〇1〇1)、甲吲洛爾 (mepindolol)、美替洛爾(metipran〇i〇i)、美托洛爾 (metoprolol)、納多洛爾(nadolol)、奈必洛爾(nebiv〇1〇1)、 硝本洛爾(nifenalol)、尼普地洛(nipra(jii〇i)、氧烯洛爾 (oxprenolol)、 噴布洛爾(penbut〇1〇1)、叫丨口朵洛爾 (pindolol)、心得安(propan〇i〇1)、沙莫特羅(salmeter〇1)、 索他洛爾(sotalol)、他林洛爾(taHn〇i〇i)、特他洛爾 (tertatolol)、替利洛爾(tiHs〇i〇i)、噻嗎洛爾(tim〇1〇1)、紮 莫特羅(xamoterol)或希苯洛爾(xiben〇1〇1)。 術語”抗咼血脂劑或抗高膽固醇血症劑,,意指選自以下之 125790.doc -48 - 200829565 化合物·氣貝特類(fibrate),例如,銘貝特(alufibrate)、 苄氣貝特(beclobrate)、苯紮貝特(bezanbrate)、環丙貝特 (ciproflbrate)、克利貝特(ciinofibrate)、降固醇酸 (clofibrate)、 依託貝特(etoHbrate)或非諾貝特 (fenofibrate);抑制素(HMG-CoA還原酶抑制劑),例如, 阿托伐他汀(atorvastatin)、敗伐他、;丁納(fluvastatin sodium)、洛伐他汀(lovastatin)、普伐他汀(pravastatin)、 羅舒伐他汀(rosuvastatin)或辛伐他汀(simvastatin),或諸 如以下之化合物:阿昔莫司(acipimox)、煙酸銘、阿紮膽 醇(azacosterol)、考來晞胺(cholestyramine)、右甲狀腺素 (dextrothyroxine)、美格魯托(meglutol)、戊四煙醋 (niceritrol)、尼可氣醋(nicoclonate)、煙驗酸、β-榖甾醇 (beta-sitosterin)或硫地醇(tiadenol) 〇 術語’’抗糖尿病劑”係指屬於以下各類之一之化合物:磺 醯脲類、雙胍類、α-葡糠苷酶抑制劑、噻唑烷二酮類、二 甲雙脈類(metiglinide),例如,酷祿、醋酸己脲、胺石黃丁 脲、氣石黃丙脲、格列本脲(glibenclamide)、格列波脲 (glibornuride)、甲石黃 π比脲(gliclazide)、格列美腺 (glimepiride)、格列 11 比喚(glipizide)、格列噎酮 (gliquidone)、格列帕特(glisoxepide)、格列丁峻 (glybuzole)、 格列嘴咬(glymidine)、 美他己脲 (metahexamide)、二甲雙脈(metformin)、米格列醇 (miglitol)、那替格列(nateglinide) 、 °比格列酮 (pioglitazone)、瑞格列奈(repaglinide)、梵帝雅 125790.doc -49- 200829565 (rosiglitazone)、妥拉石黃脲(tolazamide)、甲笨石黃丁脲 (tolbutamide)、曲格列酮(troglitazone)或伏格列波糖 (voglibose) 〇 術語”另一抗肥胖劑或作用於代謝病症之藥劑”意指諸如 以下之化合物:安非拉酮(amfepramone)、苯氟雷司 (benfluorex)、节口辰立隆(benzphetamine)、茚達雷司 (indanorex)、 馬潑尼酮(mazindole)、 美芬雷司 (mefenorex)、甲基安非他命(methamphetamine)、D-去甲麻 黃驗、西布曲明(sibutramine)、托°比S旨、脂肪酶抑制劑(奥 利斯特(orlistat)或西替利斯特(cetilistat))、PPAR促效劑 (過氧化物酶體增殖物激活受體促效劑)、多巴胺促效劑、 來普汀(leptin)受體促效劑、5-羥色胺重攝取抑制劑、β-3 促效劑、CCK-A促效劑、ΝΡΥ抑制劑、MC 4(黑皮質素4) 受體促效劑、MCH(黑色素濃集激素)受體拮抗劑、阿立新 (orexin)拮抗劑、填酸二酯酶抑制劑、UPHSDUW-羥基類 固醇脫氫酶)抑制劑、DPp-IV(二肽基肽酶IV)抑制劑、組 胺H3拮抗劑(或逆促效劑)、CNTF(睫狀神經營養因子)衍生 物、GHS (生長激素促分泌素)受體促效劑、多肽格那琳 (ghrelin)調節劑、二醯基甘油醯基轉移酶(DGAT)抑制劑、 石粦酸二酯酶(PDE)抑制劑、甲狀腺激素促效劑、糖皮質激 素受體拮抗劑、酯醯-coA去飽和酶(SCD)抑制劑、碟酸 鹽、葡萄糠、脂肪酸或二羧酸轉運蛋白調節劑、5HT2拮抗 劑、5HT6拮抗劑或鈴蟾肽促效劑。 術語”類鴉片拮抗劑”意指諸如納曲酮(naltrexone)、納洛 125790.doc -50- 200829565 酉同(naloxone)或納美芬(nalmefene)等化合物。 術語”用於治療酒精中毒或戒斷症狀之藥劑"意指阿坎酸 (acamprosate)、苯并二氮呼' p_阻斷劑、可樂定 (clonidine)及卡馬西平(carbamazepine)。 術語”用於治療骨質疏鬆症之藥劑”意指(例如)諸如依替 膦酸鹽(etidronate)、氯膦酸鹽(cl〇dr〇nate)、替魯膦酸鹽 (tiludronate)或利塞膦酸鹽(risedr〇nate)等雙膦酸鹽。 根據本發明,亦可能組合具有抗高血脂、抗高膽固醇、 抗糖尿病或抗肥胖性質之其他化合物。更具體而言,可組 合屬於以下各類之一之化合物: PTP 1 B(蛋白質酪胺酸磷酸酶_1B)抑制劑、VPAC 2受體 促效劑、GLK調節劑、類視色素調節劑、糖原磷酸化酶 (HGLPa)抑制劑、胰高血糖素拮抗劑、葡萄糖“磷酸酶抑 制劑、丙酮酸脫氫酶激酶(PDK)激活劑、RXR、fxr或 LXR調節劑、SGLT(鈉依賴性葡萄糖轉運蛋白)抑制劑、 CETP(膽固醇酯轉運蛋白)抑制劑、角鯊烯合成酶抑制劑、 角魚稀環氧酶抑制劑、甘油三g旨合成抑制劑、ldl(低密度 月曰蛋白)雙體誘導劑、IBAT^制劑、FBPase(果糖_丨,6_二磷 ^酶)抑制劑、CART(可卡因·安非他命-調節轉錄因子)調 節劑、阿立新受體拮抗劑。 根據本發明再一態樣,式⑴化合物或其醫藥上可接受之 鹽或其溶劑合物及另_經組合之活性成份可同時、單 隨時間依序投與。 〆 術μ同日守使用"意指本發明組合物之化合物係包含於相 125790.doc • 51 - 200829565 同醫藥形式中投藥。 術語"單獨使用,,意指本發明組合物之兩種化合物分別包 含於單獨醫藥形式中同時投藥。
C 術浯”隨時間依序使用"意指由包含於一醫藥形式中之本 發明組合物之第一化合物,A包含於另一單獨醫藥形式中 之本發明組合物之第二化合物依序投藥。在此情況下,根 據本發明組合物之第一化合物與根據本發明組合物之第二 化合物之投藥時間間隔一般不超過24小時。 々:經口服、舌下、皮下、肌内、靜脈内、外敷、局部、 汛吕内、鼻内、經皮或直腸投與之本發明醫藥組合物中, ^询活性成份或其可能的鹽、溶劑合物或水合物可與 仏準酉藥賦形劑形成混合物,以單位投與形式投與人類或 動物’用於預防或治療上述病症或疾病。 ^ 5,呈錠劑形式之本發明化合物之單位投與形式 可包含以下組份: 本發明化合物 m : 50.0毫克 A t且之單位投與形式包括··口服途徑劑型(例如錠劑、 权貝或硬貝明膠膠囊、㉟末、顆粒及口服溶液或懸浮 、)舌下頰内、氣管内、眼内及鼻内投與形式、藉由 及入杈與之形式、外敷、經皮、皮下、肌内或靜脈内投與 =式t直腸投與形式及植入。就外敷施用而言,可以乳 相、凝膠、膏劑或洗液使用本發明化合物。 223.75毫克 甘露醇 交聯缓甲基纖維素鈉鹽 125790.doc -52- 200829565 (Sodium croscarmellose) : 6.0 毫克 玉米澱粉 ·· 15.0毫克 經丙基甲基纖維素 : 2.25毫克 硬脂酸鎂 ·· 3.0毫克 經由口服途徑,每天所投與之活性成份的劑量可自〇.〇i 至100毫克/公斤、較佳0·02至50毫克/公斤以一或多劑量攝 取。 特殊情況下可能使用更高或更低劑量;該等劑量並不背 離本發明之範圍。根據一般操作法,適於每一患者之劑量 係由醫生根據投與方式及該患者之體重及反應而定。 根據其另一態樣,本發明係關於一種用於治療上述病狀 之方法,其包括投與患者有效劑量之本發明化合物、或其 醫藥上可接受之鹽或水合物或溶劑合物。
V 125790.doc -53-
Claims (1)
- 200829565 十、申請專利範圍: 1· 一種對應下式(I)之化合物:(1 - A代表: • (C1-C6)伸烷基,其未經取代或經(c「c3)烷基取代 一或多次; •基團-(CH2)m—立中瓜=〇、1或2且P=1或 1 ; • R1代表氫或(CVC4)烷基; -R2代表: I; · (Cs-CiG)烷基,其未經取代或經以下基團取代: 三氟甲基;羥基、(Cl-C4)烷氧基、氟原子或 • conh2基團; _ ·非芳族〇3-(:12碳環基團,其未經取代或經以下基 團取代一或多次:(G-C4)烷基、羥基、氰基或 (cvc4)烷氧基、基團cor12或氟原子; • 二氫茚基; • 1,2,3,4-四鼠-1 -或-2-蔡基; 125790.doc 200829565 5至7個原子之單氧或單硫雜環基團 或經(Ci-CJ烷基取代一或多次; 5至7個原子之單氣雜環基團,其未經取代或經 (CiO烧基取代一或多次,而且嗜 σ次乱项子再經 (CA)烧基、苯基、f基、(Ci_c4)院氧幾基i (c 1-C4)烧醯基取代’該苯基或苄基未經取代戈妙 _素原子或(C丨-C4)烧基、三氟甲基、經基Z (C1-C4)烧氧基取代一或多次;苯并嗟吩基或叫|味基,該等基團未經取代或經 (C1-C4)烧基取代一或多次; 具有非芳族C3-Ci〇碳環基團之(c^c:3)伸燒基,其 未經取代或經(C「C4)燒基、羥基、(CrCd烧氧基 或氣基或基團(1;0尺12取代一或多次;,其未經取代 具有含5至7個原子之單氧、單硫或單氮雜芳族或 非雜芳族雜環基團之(C^C:3)伸烧基,其未經取代 或經(Ci-C4)烷基取代一或多次; 具有吲哚基或苯并噻吩基之(C^CJ伸烷基,該吲 ϋ朵基或苯并噻吩基未經取代或經(Cl_C4)烷基取代 一或多次且該伸烷基未經取代或經羥基、甲基或 T氧基或經基團COR12取代; 具有(CVC4)烷硫基之(Ci-C3)伸烷基; 其中伸烷基為(Ci-CO之苯基伸烷基,該伸烷基上 未經取代或經一個或多個甲基、羥基、羥基甲 基、甲氧基或甲氧基甲基或基團COR12取代,且 125790.doc 200829565 該苯基上未經取代或在該苯基上經一或多個選自 函素原子及(Cl-c4)燒基、三氧甲基、(Μ)烧氧 基或三敦甲氧基之相同或不同取代基取代; •二苯甲基或二笨甲基甲基; •基團 NR10Rn ; 或RlAR2連同其所連接之氮原子-起構成: • 嗎基, . 或六氫吡嗪-1-基或14 一备 Γ Ο 一 土及i4-一虱呼_1_基,其未經取代 或、、二本基、节基、苯并間二氧雜環戊稀基、苯并 間二氧雜環戊稀基甲基或四氣咬喃基幾基或經基 團c〇rmCH2CORi2取代,該节基本身未經取代 或Ί 或多個_素原子取^ 、 甲于取代或經一或多個曱氧基 或甲氧基甲基取代; •或/、氣。比°定_ 1 -基、°比略。定_ 1其> 令疋1-基或氮雜環丁烷^- 基,其未經取代或經獨立選自下列之取代基取代 一或兩次: •氣原子或基團(Cl-C4)燒基、經基、氰基、 C0RU、取 13R14、NHC0R15 SOWk;或 s〇2NRi3Ri4 ; 本基、苄基或吼it定基,該笼其 m成本基、苄基或吡啶基基 團未經取代或經各自獨立選自幽素原子及甲基、 甲:、經基、(Cl-C4)燒氧基或氛基之取代基 取代一或多次; /、氣比。疋_ 1 _基、〇比洛 _ 基或氮雜環丁烷-1 - 125790.doc 200829565 基,該六氫吡啶-1-基、吡咯啶-ι·基或氮雜環丁 烷-1-基基團未經取代或經氟原子或(Ci-Cd烷基、 (Ci-CJ烷氧基、羥基、三氟甲基或OCF3基團取代 一或多次;C -R3、及4、R5、R6、尺7及化8各自獨立代表氫或鹵素原 子、基團CN、S(0)nALK或0S(0)nALK、未經取代或 經各自獨立選自氟原子及基團OALK、S(0)nALK、 OS(0)nALK及NHS02Alk之取代基取代一或多次的基 團(CrC?)烷基、或未經取代或經一或多個各自獨立 選自氟原子及基團OALK、S(0)nALK、0S(0)nALK 及NHS02Alk之取代基取代的基團(CrCJ烷氧基; - R9代表基團-OH、-CN、-C02H、NR13R14、-CONR13R14 、-NR^CORu、-CONHNH2、-CONHOH、-C0NHS02Alk 、-S(0)nAlk、-S02CF3、-S02NR13R14、NRiSC^Alk 、-NRiSC^CFs、-NRiSC^NRuRw ;或選自下列之基 團:125790.doc -4 200829565 汉10表示氲原子或甲基; _〜代表(C3-c6)院基、苯基或(C3_Ci。)環院基,該苯 基及環燒基基團未經取代或經—或多個獨立選自齒 素原子及(CrC4)烷基或三氟甲基之取代基取代; -或R】。及Rn連同其所連接之氮原子—起構成餘和或 不飽和、橋接或非橋接之4至U個原子之雜環基團, 該,環基團可能包含螺環烧碳且可能包含選自 之第二雜原子,該基團未經取代或經各自獨立選自 羥基、((VC4)烷基或(Ci_C4)烷氧羰基或cola基 團、或苯基取代-或多次,該苯基未經取代或經一 或多個獨立選自齒素原子及(Ci_C4)烷基之取代基取 代; -Rl2代表(Ci_C4)烷基、苯基、苄基、(CVC4)烷氧基或 二氟甲基或基團NR13R14 ; -Rl3及Rh各自獨立代表氫原子或視情況經一或多個 基團OH、F或OALK取代之(Cl-C6)烷基,或^3或^4 連同其所連接之氮原子一起構成可能包含選自氮、 氧或硫原子之4·至7-員雜環基團; R15代表(C1-C4)烧基或三敦甲基; - η表示〇、1或2; -ALK代表(Ci-C4)烷基,其未經取代或經一或多個氣 原子取代; - Aik代表(Ci-C4)烷基; 其呈驗形式或酸加成鹽形式,以及其鹽、溶劑合物及水 125790.doc 200829565 合物。 2·如請求項1之式(I)化合物,其中·· -Ri代表氫且h代表基團NR1〇Rll,其中Rl〇及Rn連同 其所連接之氮原子一起構成5至11個碳原子的飽和雜 壤基團’其未經取代或經(Ci_c4)烷基取代一或多 次; -或Ri及R2連同其所連接之氮原子一起構成六氫吼 啶-1-基,其經苯基、苄基、吡咯啶_卜基、六氫吡 啶-1-基或4,4-二氟六氫吡啶基、氰基、(C1_C3)烷 醯基、胺基羰基、甲烷磺醯基、N-甲基磺醯基或 N,N-二甲基石黃醒基偕_雙取代; -或Rl與R2 一起代表六氫吨嗪-1-基,其經苯并間二氧 雜環戊烯基或苯并間二氧雜環戊烯基甲基或經苄基 4-取代,該苄基本身未經取代或經一或多個幽素原 子取代或經一或多個甲氧基或甲氧基〒基取代 -及/或R3、R4、R5、r6、RAr8各自獨立代表氫或鹵 素原子或甲氧基; A-R9如請求項1中(I)所定義之一; 以及其鹽、溶劑合物及水合物。 3·如請求項1之式(I)化合物,其中: -R1代表氫且R2代表六氫吼啶-1-基或(Cl-C3)伸烷基基 團,其經苯基及經甲氧基或甲氧羰基取代; -或R1代表氫且R2代表其中伸烷基為(Cl_C3)伸烷基之 苯基伸烷基,該伸烷基上未經取代或在該伸烷基上 125790.doc 200829565 經甲基、羥基、羥基甲基、甲氧基或甲氧基甲基取 代,且在該苯基上未經取代或在該苯基上經鹵素原 子或甲基、二氟甲基、經基或甲氧基取代一或多 次; - 或&及I連同其所連接之氮原子一起代表六氫吼啶_ 1-基,其經苯基或六氫吡啶基且經醯基、胺基羰 基或氰基4-偕-雙取代; - 或Rl及R2 一起代表六氫吼嗪-1 -基,其經苯并間二氧 雜環戊烯基甲基或苄基4_取代,該苄基自身未經取 代或經鹵素原子取代; -R6為4·氣或甲氧基且R3及R4代表2,4-二氯或2·氣; R5、R7及代表氫原子; • A代表基團(CH2)q,其中q=2、3、4或5 ; -R9代表選自-C02H、-NHS〇2CF3、-NHS02CH3、 -so2ch3之基團; 以及其鹽、溶劑合物及水合物。 4. 如請求項1之式(I)化合物,其中: -NIR2代表: —N〇 -N N-CH.CH2-OMe -NH-CH-CH. fNH2 〇125790.doc 200829565'R3、R4&R6各自代表函素原子; "R5、R7及R8各自代表氫原子; A代表苄基或(c^C5)伸烷基,其未經取代或經甲基 取代一或多次; 尺9 代表基團 CN、co2H、S02CH3、nhso2ch3 或 NHS02CF3 ; 以及其鹽、其溶劑合物及其水合物。 一種製備如請求項i之人k L 、之式(1)化合物之方法,其特徵在 用其中RAR2係如式⑴所定義的式HNH⑽胺處 理如下式(II)之酸或此酸的功能衍生物:卜 "八八8'叩郊八(I 氧原子或基團A-r9、或基 ’广 6. :二適宜,將該取代基Y轉化為基二 種下式之化合物: 125790.doc 200829565 Ο II(II 雙) 其中 -X代表鹵素原子或羥基、(C^CO烷氧基或苄氧基; - A代表: • (Ci-C6)伸烷基,其未經取代或經(c^Cs)烷基取 代一或多次; •基團-(CH2)n;~^ 其中m=0、1或2且p=l或 (CH2)p- 1 ; -R3、R4、R5、R6、R7及R8各自獨立代表氮或鹵素原 子、(CVC6)烷氧基、基團 S(0)nALK、0S(0)nALK或 (C1-C7)烧基’其未經取代或經氟原子或基團 OALK、S(0)nALK或 0S(0)nALK取代一或多次; -R9代表基團 _OH、-CN、-CO2H、NR13R14、-CONR13R14 、-CONHNH2、-CONHOH、-C0NHS02Alk、 -S(0)nAlk、_S02CF3、_S02NR13R14、-NHS02Alk、 -NHS02CF3、-NR^SC^NRuRh ;或選自下歹!J 之基 團: 125790.doc -9- 200829565( -ALK代表(C「C4)烷基,其未經取代或經一或多個氟 原子取代; Aik代表(C1-C4)烧基。 7. 一種藥物,其特徵在於其包含如請求項丨至4中任一項之 式(I)化合物或該化合物與醫藥上可接受之酸形成之加成 鹽或者該式(I)化合物之水合物或溶劑合物。 8. -種醫藥組合物,其特徵在於其包含如請求項⑴中任 -項之式⑴化合物或該化合物之水合物或溶劑合物以及 至少一種醫藥上可接受之賦形劑。 9. 一種如請求項!至4中所定 ,疋我之式(I)化合物用於製備 或預防與CBi受體相M^ 表備/口療 體相關之疾病之藥物的用途。 1〇·如請求項9之用途,苴料 #此 八特政在於遠專疾病為精神疾癍、 賴及戒断病症、認知障礙、注意力 及急性及慢性神經退行性疾病。 早礙、 Π ·如請求項9之用途,1 /、特被在於該等疾病么 慾望障礙、食欲章 、〜、代谢病症、 民心丨手礙、肥胖症 J U型搪尿病、代謝症候 I25790.doc -10- 200829565 群及血脂異常。 12 13. 14. 15. 神經 月长項9之用途,其特徵在於該等疾广 生疼痛或由抗癌治療引起之疼痛。 租,項9之用途,其特徵在於該等疾 症、嘔吐、腹瀉、潰瘍及肝病。 、’、胃腸失調 如明求項9之用途,其特徵在於 病、類®、、H k ^辰届係免疫系統疾 、/…、性關節炎、脫髓鞘、多發性硬化 病。 x 及炎症性疾 阿茲海默氏 糖尿病、肥 二叫求項9之用途,其特徵在於該等疾病為 ^帕金森氏症、精神分裂症、認知障礙、 胖症、代謝症候群及菸瘾戒斷病症。 125790.doc 200829565 七、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:125790.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0610202A FR2908766B1 (fr) | 2006-11-20 | 2006-11-20 | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200829565A true TW200829565A (en) | 2008-07-16 |
Family
ID=38521242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096143731A TW200829565A (en) | 2006-11-20 | 2007-11-19 | Pyrrole derivatives, preparation thereof and therapeutic use thereof |
Country Status (27)
Country | Link |
---|---|
US (1) | US8044072B2 (zh) |
EP (1) | EP2094656B1 (zh) |
JP (1) | JP5210320B2 (zh) |
KR (1) | KR20090080992A (zh) |
CN (1) | CN101535250A (zh) |
AR (1) | AR064596A1 (zh) |
AT (1) | ATE520654T1 (zh) |
AU (1) | AU2007330651A1 (zh) |
BR (1) | BRPI0718962A2 (zh) |
CA (1) | CA2669996A1 (zh) |
CL (1) | CL2007003318A1 (zh) |
CR (1) | CR10772A (zh) |
DO (1) | DOP2009000105A (zh) |
EA (1) | EA200970497A1 (zh) |
EC (1) | ECSP099339A (zh) |
FR (1) | FR2908766B1 (zh) |
IL (1) | IL198481A0 (zh) |
MA (1) | MA30996B1 (zh) |
MX (1) | MX2009005366A (zh) |
NO (1) | NO20092066L (zh) |
PE (1) | PE20081495A1 (zh) |
SV (1) | SV2009003265A (zh) |
TN (1) | TN2009000166A1 (zh) |
TW (1) | TW200829565A (zh) |
UY (1) | UY30729A1 (zh) |
WO (1) | WO2008068423A2 (zh) |
ZA (1) | ZA200903865B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2930939B1 (fr) * | 2008-05-09 | 2010-07-30 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
FR2930940B1 (fr) * | 2008-05-09 | 2011-02-11 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
CN102964304B (zh) * | 2012-09-28 | 2015-06-17 | 苏州大学 | 含吡唑烷酮结构的手性氨基氰化物的制备方法 |
RU2711991C1 (ru) * | 2016-07-12 | 2020-01-23 | Гуандун Рейновент Биотек Ко., Лтд. | Производные пирролидина в качестве агонистов ppar |
RU2749056C1 (ru) | 2017-12-21 | 2021-06-03 | Гуандун Рэйновент Байотек Ко., Лтд. | Аморфное производное пирролидина в качестве агониста ppar и способ его получения |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
DK1756066T3 (da) * | 2004-05-28 | 2008-12-15 | Solvay Pharm Bv | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
FR2881744B1 (fr) * | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
JP2008530179A (ja) * | 2005-02-16 | 2008-08-07 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | カンナビノイドcb2受容体モジュレーターとしての1h−イミダゾール誘導体 |
-
2006
- 2006-11-20 FR FR0610202A patent/FR2908766B1/fr not_active Expired - Fee Related
-
2007
- 2007-11-16 PE PE2007001599A patent/PE20081495A1/es not_active Application Discontinuation
- 2007-11-19 EA EA200970497A patent/EA200970497A1/ru unknown
- 2007-11-19 CA CA002669996A patent/CA2669996A1/fr not_active Abandoned
- 2007-11-19 ZA ZA200903865A patent/ZA200903865B/xx unknown
- 2007-11-19 CN CNA2007800429161A patent/CN101535250A/zh active Pending
- 2007-11-19 AR ARP070105123A patent/AR064596A1/es unknown
- 2007-11-19 CL CL200703318A patent/CL2007003318A1/es unknown
- 2007-11-19 AU AU2007330651A patent/AU2007330651A1/en not_active Abandoned
- 2007-11-19 AT AT07870294T patent/ATE520654T1/de not_active IP Right Cessation
- 2007-11-19 WO PCT/FR2007/001888 patent/WO2008068423A2/fr active Application Filing
- 2007-11-19 BR BRPI0718962-1A patent/BRPI0718962A2/pt not_active Application Discontinuation
- 2007-11-19 KR KR1020097010256A patent/KR20090080992A/ko not_active Application Discontinuation
- 2007-11-19 EP EP07870294A patent/EP2094656B1/fr active Active
- 2007-11-19 JP JP2009536763A patent/JP5210320B2/ja not_active Expired - Fee Related
- 2007-11-19 TW TW096143731A patent/TW200829565A/zh unknown
- 2007-11-19 MX MX2009005366A patent/MX2009005366A/es not_active Application Discontinuation
- 2007-11-20 UY UY30729A patent/UY30729A1/es not_active Application Discontinuation
-
2009
- 2009-04-29 TN TNP2009000166A patent/TN2009000166A1/fr unknown
- 2009-04-30 IL IL198481A patent/IL198481A0/en unknown
- 2009-05-06 CR CR10772A patent/CR10772A/es not_active Application Discontinuation
- 2009-05-11 DO DO2009000105A patent/DOP2009000105A/es unknown
- 2009-05-14 US US12/465,893 patent/US8044072B2/en not_active Expired - Fee Related
- 2009-05-15 SV SV2009003265A patent/SV2009003265A/es unknown
- 2009-05-18 EC EC2009009339A patent/ECSP099339A/es unknown
- 2009-05-27 NO NO20092066A patent/NO20092066L/no not_active Application Discontinuation
- 2009-06-15 MA MA31995A patent/MA30996B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AR064596A1 (es) | 2009-04-15 |
JP5210320B2 (ja) | 2013-06-12 |
WO2008068423A3 (fr) | 2008-07-31 |
JP2010510198A (ja) | 2010-04-02 |
EP2094656B1 (fr) | 2011-08-17 |
US20090281116A1 (en) | 2009-11-12 |
PE20081495A1 (es) | 2008-12-31 |
CN101535250A (zh) | 2009-09-16 |
EA200970497A1 (ru) | 2009-10-30 |
FR2908766A1 (fr) | 2008-05-23 |
CR10772A (es) | 2009-07-23 |
WO2008068423A2 (fr) | 2008-06-12 |
ZA200903865B (en) | 2010-08-25 |
TN2009000166A1 (fr) | 2010-10-18 |
ECSP099339A (es) | 2009-06-30 |
DOP2009000105A (es) | 2009-05-31 |
EP2094656A2 (fr) | 2009-09-02 |
CA2669996A1 (fr) | 2008-06-12 |
AU2007330651A1 (en) | 2008-06-12 |
BRPI0718962A2 (pt) | 2013-12-17 |
MA30996B1 (fr) | 2009-12-01 |
FR2908766B1 (fr) | 2009-01-09 |
CL2007003318A1 (es) | 2008-07-04 |
UY30729A1 (es) | 2008-07-03 |
NO20092066L (no) | 2009-08-11 |
US8044072B2 (en) | 2011-10-25 |
ATE520654T1 (de) | 2011-09-15 |
MX2009005366A (es) | 2009-06-08 |
KR20090080992A (ko) | 2009-07-27 |
SV2009003265A (es) | 2010-02-05 |
IL198481A0 (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20070103454A (ko) | 1,5-디아릴피롤 유도체, 그의 제조 방법, 및 치료제에서의그의 적용 | |
TW200836739A (en) | Substituted 2, 5-dihydro-3H-pyrazolo[4, 3-c] pyridazin-3-one derivatives, preparation thereof and therapeutic use thereof | |
TW200829565A (en) | Pyrrole derivatives, preparation thereof and therapeutic use thereof | |
JP5142152B2 (ja) | 4,5−ジアリールピロール誘導体、この調製方法および治療におけるこの使用 | |
US7879902B2 (en) | Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof | |
US8088797B2 (en) | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | |
US8680102B2 (en) | Pyrrole derivatives, their preparation and their therapeutic application | |
US7541361B2 (en) | N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use | |
JP5607027B2 (ja) | ピロール誘導体、この調製、およびカンナビノイドcb1受容体アンタゴニストとしてのこの治療用途 |